Page last updated: 2024-10-23

bisoprolol and Syndrome

bisoprolol has been researched along with Syndrome in 2 studies

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Syndrome: A characteristic symptom complex.

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kneissl, GD	1
Burger, W	1
Meixensberger, J	1
Friedrich, F	1
Kortmann, RD	1
Freitas, J	1
Santos, R	1
Azevedo, E	1
Costa, O	1
Carvalho, M	1
de Freitas, AF	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730]			Phase 1/Phase 2	8 participants (Actual)	Interventional	2011-08-15	Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Blood Pressure From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Fatigue Score on the Chalder Fatigue Questionnaire From Baseline

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Heart Rate From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Muscle Sympathetic Nerve Activity From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- 7 Item Patient Global Impression of Change From Baseline

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning- HADS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-CIS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-EuroQOL From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-FSS From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-MFI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-OI From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Physical Functioning-SF-36 Q From Baseline

Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change in Vascular Resistance From Baseline

(NCT03070730)
Timeframe: 1 week after third intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Change Maximal Postural Tachycardia During Tilt

Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention

Intervention	()
Atenolol	0
Placebos	0
Droxidopa	0

Trials

1 trial available for bisoprolol and Syndrome

Article	Year
Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2000, Volume: 10, Issue:5 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Bisoprolol; Blood Pressure; Cardiac Output; Electroc	2000

Other Studies

1 other study available for bisoprolol and Syndrome

Article	Year
Holiday heart syndrome possibly triggered after the start of radiochemotherapy for glioblastoma multiforme. Cardiology, 2006, Volume: 105, Issue:2 Topics: Adrenergic beta-Antagonists; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bi	2006